SCHEMBL14744718

SCHEMBL14744718

Cc1cc2[nH]c(-c3[nH]c(=O)cc(O)c3C)cc2cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 5/20 0.38
BRD4 O60885 1/20 0.33
KDM4E B2RXH2 4/20 0.32
ALDH1A1 P00352 4/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 3/20 0.31
GLA P06280 2/20 0.31
GAA P10253 1/20 0.31
PLAU P00749 1/20 0.31
PLAT P00750 1/20 0.31
KLKB1 P03952 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
F7 P08709 1/20 0.31
PRSS3 P35030 1/20 0.31
ERN1 O75460 1/20 0.31
DDO Q99489 2/20 0.31
USP2 O75604 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14746103 0.85 DAO (0.35) DAOKDM4EALDH1A1MAPTHPGD
SCHEMBL14745749 0.76 BRD4 (0.35) DAOBRD4KDM4EALDH1A1MEN1
SCHEMBL14744817 0.68 HSD17B10 (0.33) DAOKDM4EALDH1A1MAPTHPGD
SCHEMBL30908315 0.66 CA12 (0.55) DAOBRD4MAPTDDO
SCHEMBL4568269 0.66 NPC1 (0.53) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL4568270 0.66 CYP1A1 (0.52) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL17429451 0.64 EIF4A3 (0.65) DAOKDM4EALDH1A1KMT2AMAPT
SCHEMBL4568273 0.63 CYP19A1 (0.58) ALDH1A1KMT2A
SCHEMBL15998605 0.63 CYP1A1 (0.40) DAOKDM4EALDH1A1MEN1KMT2A
SCHEMBL27308379 0.62 DAO (0.39) DAOKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP DAO 558/4885BRD4 2439/4885KDM4E 4305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.